Thomas Flatton

“Rob, you mentioned you had some pretty positive commentary coming out of your meeting with the Merck, Millipore, Sigma folks, including having them contribute more meaningfully in the second half.”

“Just on the sales team dynamics, you guys added maybe a couple of heads fewer than I was expecting, but it seems like you're going to ramp hiring in the second half of the year.”

“Sy, just perhaps an obvious question, but I want to ask it. With the, I think anchoring is the word you used in the derms versus peds, does that align with how your targeting is designed as well, or is that just more happenstance where derms have been the quicker adopters and peds are coming on board later?”

“I was wondering if there's any way you could characterize the Millipore sales funnel from an industrial vertical perspective. What's their focus? What are they looking at?”

“Just to confirm on the salesforce expansion, in your letter you talked about hiring about 100 folks. If I'm understanding, 50 of them went to the V-Vice sales team to effectively double that team.”